Nrf-2/HMOX-1-IN-1

Nrf-2/HMOX-1-IN-1 (Compound 10) (0-192 μM; 48 h) selectively inhibits the viability of MCF-7 breast cancer cells (IC₅₀ = 51.82 μM) and A549 lung cancer cells (IC₅₀ = 68.33 μM), while shows low toxicity to WI-38 normal fibroblasts after 48 h of incubation (IC₅₀ = 208.3 μM)^[1].
Nrf-2/HMOX-1-IN-1 (25.91-51.82 μM; 48 h) induces dose-dependent morphological changes associated with ferroptosis in MCF-7 breast cancer cells after 48 h of incubation^[1].
Nrf-2/HMOX-1-IN-1 (25.91-51.82 μM; 48 h) dose-dependently increases the intracellular ROS level in MCF-7 breast cancer cells, and the ROS accumulation rate reaches 75.5% after incubation at the IC₅₀ concentration for 48 hours^[1].
Nrf-2/HMOX-1-IN-1 (25.91-51.82 μM) dose-dependently downregulates the expression of Nrf-2 protein in MCF-7 breast cancer cells, with a relative expression level of 0.155 at the IC₅₀ concentration^[1].
Nrf-2/HMOX-1-IN-1 (25.91-51.82 μM) increases the level of lipid peroxidation in MCF-7 breast cancer cells in a dose-dependent manner (the maximum MDA level reaches 2.47 nmol/mg protein) and reduces their antioxidant defense capacity (the GSH level decreases to 5.13 mg/g protein, and the GPX activity decreases to 6.43 U/mg protein) after 48 h of incubation^[1].
Nrf-2/HMOX-1-IN-1 (25.91-51.82 μM) dose-dependently increases intracellular iron levels in MCF-7 breast cancer cells, with iron levels reaching up to 60.1 mmol/mL at the IC₅₀ concentration^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.